Browse the evidence

African American women with obesity and low insulin sensitivity lose significantly more fat mass and maintain higher total energy expenditure when following a low-carbohydrate diet compared to a low-fat diet.

If you are an African American woman with obesity and have struggled to lose weight on standard low-fat diets, switching to a low-carbohydrate approach (around 20% carbs, 55% fat) may help you lose more fat and keep your metabolism higher. This benefit is specifically linked to having lower insulin sensitivity, which is common in this demographic. Focus on whole foods, complex carbohydrates, and healthy fats while maintaining a caloric deficit.

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.

If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.

GIP has pleiotropic effects beyond glucose metabolism, including potential benefits for obesity, bone health, and neurodegenerative disorders, making it a candidate for pharmacotherapies.

GIP is not just a blood sugar hormone. It also influences fat storage, bone density, and brain health. This is why new drugs that mimic or modify GIP are being studied for obesity and even neurodegenerative diseases.

GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.

GLP-1 medications also work in the brain's 'hunger center' (arcuate nucleus) by boosting 'stop eating' signals (POMC) and reducing 'start eating' signals (NPY/AgRP). This dual action helps reduce overall food intake and body weight.

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

Tirzepatide treatment (5-15 mg once weekly) reduces albuminuria (UACR) without causing adverse changes in estimated glomerular filtration rate (eGFR) in individuals with overweight or obesity, with or without type 2 diabetes.

If you have overweight or obesity, with or without type 2 diabetes, tirzepatide (a weekly injection) has been shown to improve kidney markers (specifically reducing albuminuria) without negatively impacting kidney filtration function. This benefit was observed across different doses (5-15 mg) over 72 weeks, alongside lifestyle changes. This suggests it may be a kidney-protective option for this population, particularly those with existing elevated albuminuria.

Multi-receptor incretin drugs significantly reduce systolic and diastolic blood pressure, with Tirzepatide and Mazdutide showing the most substantial reductions, particularly in non-diabetic populations.

If you have high blood pressure along with overweight or obesity, multi-receptor incretin drugs can help lower both systolic and diastolic blood pressure. This effect is often stronger in people without type 2 diabetes. Discuss with your doctor if these medications could help manage your blood pressure as part of your overall treatment plan.

Diabetes remission, rather than weight loss itself, is the primary driver for reducing the risk of new-onset microvascular complications.

While weight loss is important, achieving diabetes remission (normal blood sugar without medication) is what actually protects against microvascular complications like kidney and eye damage. Weight loss without remission may not provide this specific protection.

Obesity significantly increases the risk of cardiovascular disease, heart failure, and cerebrovascular disease, even in individuals classified as 'metabolically healthy'.

If you have obesity, your risk for heart disease and heart failure is significantly higher than someone with a normal weight, even if your blood pressure and cholesterol are currently normal. You should prioritize cardiovascular health monitoring and weight management strategies to mitigate this elevated risk.

Semaglutide demonstrates superior efficacy compared to Liraglutide in reducing hemoglobin A1c (HbA1c) levels, though it shows no significant difference in weight loss or fasting blood sugar (FBS) reduction compared to Liraglutide.

If you are managing Type 2 Diabetes without metformin, switching from Liraglutide to Semaglutide is likely to improve your blood sugar control (HbA1c) more effectively. However, do not expect significantly more weight loss from this switch alone, as both drugs appear to offer similar weight reduction benefits.

Semaglutide demonstrates superior efficacy compared to Dulaglutide in reducing both HbA1c and Fasting Blood Sugar (FBS), but shows no significant difference in weight loss or BMI reduction.

If you are using Dulaglutide and your blood sugar (HbA1c and FBS) is not well-controlled, switching to Semaglutide may offer better glycemic results. However, if your primary goal is weight loss, switching is unlikely to yield additional weight reduction compared to staying on Dulaglutide.

Higher estimated glucose disposal rate (eGDR), indicating lower insulin resistance, is independently associated with a reduced risk of incident cardiovascular disease in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.

For individuals with metabolic risk factors (obesity, high blood pressure, or pre-diabetes), improving insulin sensitivity is a primary strategy for preventing heart disease. While eGDR is a clinical metric, the underlying principle is that reducing insulin resistance—through weight management, physical activity, and dietary quality—lowers cardiovascular risk. This benefit is most pronounced in early stages of metabolic dysfunction (CKM 0-1).

Statin therapy is safe and effective for cardiovascular risk reduction in patients with MASLD and MASH, and elevated transaminases should not prevent prescription.

If you have fatty liver disease (MASLD/MASH), do not avoid statins due to fear of liver damage. Statins are safe, effective for heart health, and may even improve liver markers. Consult your doctor for appropriate intensity based on your overall cardiovascular risk.

Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.

If you are obese and have HFpEF, ask your doctor about semaglutide (Ozempic/Wegovy). The STEP-HFpEF trial showed that taking 2.4 mg once weekly significantly improved quality of life and reduced body weight by over 13% compared to placebo.

Next-generation incretin-based therapies (GLP-1 RAs like semaglutide and dual GLP-1/GIP agonists like tirzepatide) significantly reduce blood pressure and improve cardiovascular outcomes in patients with hypertension, obesity, or type 2 diabetes, acting through both weight loss and direct tissue effects on the cardiovascular system.

If you have high blood pressure, obesity, or type 2 diabetes, ask your doctor about GLP-1 or GLP-1/GIP medications like semaglutide or tirzepatide. These weekly injections not only help with weight loss but also directly lower blood pressure and protect your heart, often allowing you to reduce or stop other blood pressure medications. The benefits extend beyond weight loss through direct effects on your blood vessels and nervous system.

Testosterone therapy preserves lean mass and reduces fat mass when used as an adjunct to incretin-based weight loss medications, potentially counteracting sarcopenia.

Current evidence does not yet support using testosterone to offset muscle loss from GLP-1 weight loss drugs. Resistance exercise and adequate protein intake are the recommended strategies to preserve muscle mass during weight loss.

Genetically modeled GLP-1 and GIP receptor agonism reduces the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) and lowers ALT levels.

Genetic evidence suggests that activating GLP-1 and GIP receptors improves liver health by reducing the risk of NAFLD and lowering ALT levels. This benefit is independent of alcohol consumption, suggesting a direct metabolic effect on the liver.

Mono- and multireceptor agonists combining proglucagon-derived peptides enhance efficacy in managing obesity, diabetes, and conditions affecting the kidneys, liver, and heart.

New combination therapies that target multiple receptors (e.g., GLP-1/GIP, GLP-1/Glucagon) are showing enhanced efficacy for managing obesity, diabetes, and cardiometabolic conditions. Discuss these advanced options with your healthcare provider if standard treatments are insufficient.

Incretin-based pharmacotherapies (GLP-1, GIP, and triple agonists) significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression compared to placebo, primarily through weight loss and insulin sensitization, with some agents showing direct hepatic benefits.

For patients with MASH, incretin-based therapies like Semaglutide (2.4mg weekly) are highly effective at resolving liver inflammation and improving fibrosis, often outperforming placebo in clinical trials. While gastrointestinal side effects are common, they can be managed with careful dosing and dietary adjustments, making these drugs a viable and potent option for those who struggle with lifestyle changes alone.

Tirzepatide provides clinically meaningful HbA1c reduction and dose-proportional weight loss in older adults (≥65 years) with type 2 diabetes who do not have obesity (BMI < 30 kg/m2), without increasing hypoglycemic risk compared to the general population.

If you are over 65 and have type 2 diabetes but are not obese (BMI under 30), tirzepatide is a viable treatment option. It effectively lowers blood sugar and promotes weight loss without increasing the risk of dangerous low blood sugar, provided you are not already on insulin or sulfonylureas. Be aware that gastrointestinal side effects are common, but generally mild, and discontinuation rates due to side effects are slightly higher in this group than in the general population.

GLP-1 receptor agonists (GLP-1RA) and dual/triple incretin agonists significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution without worsening fibrosis in patients with MASLD, primarily through indirect mechanisms involving weight loss, improved insulin sensitivity, and reduced hepatic lipogenesis.

If you have fatty liver disease (MASLD/MASH), especially with type 2 diabetes or obesity, GLP-1 based medications (like semaglutide or tirzepatide) are currently the most promising pharmacological treatment. They work by reducing liver fat, inflammation, and improving insulin sensitivity. While they may cause temporary stomach issues, they significantly increase the chance of resolving liver inflammation (MASH). The goal is to stop liver damage progression; fibrosis reversal is still being studied in larger trials. Consult a hepatologist or diabetologist for eligibility.

Long-term stable use of GLP-1 receptor agonists results in attenuated gastric emptying effects (tachyphylaxis) compared to recent initiation, reducing perioperative risk.

If you have been on your GLP-1 shot for months, your body has likely adapted, and your stomach empties more normally than when you first started. This makes surgery safer for you than for someone who just started the drug two weeks ago.

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.